Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis
<p>Abstract</p> <p>Background</p> <p>To investigate the association between myositis autoantibodies and clinical subsets of inflammatory myositis in Korean patients.</p> <p>Methods</p> <p>Immunoprecipitation was performed using the sera of classi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-09-01
|
Series: | BMC Musculoskeletal Disorders |
Online Access: | http://www.biomedcentral.com/1471-2474/11/223 |
id |
doaj-ef448a1781584f779f45c0436fa8026c |
---|---|
record_format |
Article |
spelling |
doaj-ef448a1781584f779f45c0436fa8026c2020-11-24T20:53:23ZengBMCBMC Musculoskeletal Disorders1471-24742010-09-0111122310.1186/1471-2474-11-223Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositisLee YunKim JinhyunMimori TsuneyoNakashima RanKang EunLee EunSong Yeong<p>Abstract</p> <p>Background</p> <p>To investigate the association between myositis autoantibodies and clinical subsets of inflammatory myositis in Korean patients.</p> <p>Methods</p> <p>Immunoprecipitation was performed using the sera of classic polymyositis (PM) (n = 11) and dermatomyositis (DM) (n = 38) patients who met the Bohan and Peter criteria for definite inflammatory myositis. A panel of defined myositis autoantibodies was surveyed to investigate the association between each autoantibody and clinical subsets of inflammatory myositis.</p> <p>Results</p> <p>Either MSAs, anti-p140, or anti-p155/140 antibodies were found in 63.3% (31/49) of the study subjects. Anti-140-kDa-polypeptide (anti-p140) (18.4%, 9/49) and anti-155/140-kDa polypeptide (anti-p155/140) (16.3%, 8/49) antibodies were the most common, followed by anti-Mi2 (14.3%, 7/49), anti-ARS (12.2%, 6/49) and anti-SRP (2.0%, 1/49) antibodies. All MSAs and anti-p140 and anti-p155/140 antibodies were mutually exclusive. Anti-p140 (23.7%, 9/38), anti-p155/140 (21.1%, 8/38), and anti-Mi2 (18.4%, 3/38) antibodies were found exclusively in DM patients. Anti-p140 antibody was associated with rapidly progressive interstitial lung disease (ILD) (p = 0.001), with a sensitivity of 100.0% (4/4) and a specificity of 85.3% (29/34) in DM patients. Anti-p155/140 antibody was associated with cancer-associated DM (p = 0.009), with a sensitivity of 55.6% (5/9) and a specificity of 89.7% (26/29). Cancer-associated survival was significantly worse when anti-p155/140 antibody was present (19.2 ± 7.6 vs. 65.0 ± 3.5 months, p = 0.032). Finally, anti-ARS antibodies were associated with stable or slowly progressive ILD in PM and DM patients (p = 0.005).</p> <p>Conclusions</p> <p>Anti-p140 and anti-p155/140 antibodies were commonly found autoantibodies in Korean patients with inflammatory myositis. Despite the lack of clinically amyopathic DM patients in the study subjects, a strong association was observed between anti-p140 antibody and rapidly progressive ILD. Anti-p155/140 antibody was associated with cancer-associated myositis and poor survival.</p> http://www.biomedcentral.com/1471-2474/11/223 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lee Yun Kim Jinhyun Mimori Tsuneyo Nakashima Ran Kang Eun Lee Eun Song Yeong |
spellingShingle |
Lee Yun Kim Jinhyun Mimori Tsuneyo Nakashima Ran Kang Eun Lee Eun Song Yeong Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis BMC Musculoskeletal Disorders |
author_facet |
Lee Yun Kim Jinhyun Mimori Tsuneyo Nakashima Ran Kang Eun Lee Eun Song Yeong |
author_sort |
Lee Yun |
title |
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis |
title_short |
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis |
title_full |
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis |
title_fullStr |
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis |
title_full_unstemmed |
Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis |
title_sort |
myositis autoantibodies in korean patients with inflammatory myositis: anti-140-kda polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis |
publisher |
BMC |
series |
BMC Musculoskeletal Disorders |
issn |
1471-2474 |
publishDate |
2010-09-01 |
description |
<p>Abstract</p> <p>Background</p> <p>To investigate the association between myositis autoantibodies and clinical subsets of inflammatory myositis in Korean patients.</p> <p>Methods</p> <p>Immunoprecipitation was performed using the sera of classic polymyositis (PM) (n = 11) and dermatomyositis (DM) (n = 38) patients who met the Bohan and Peter criteria for definite inflammatory myositis. A panel of defined myositis autoantibodies was surveyed to investigate the association between each autoantibody and clinical subsets of inflammatory myositis.</p> <p>Results</p> <p>Either MSAs, anti-p140, or anti-p155/140 antibodies were found in 63.3% (31/49) of the study subjects. Anti-140-kDa-polypeptide (anti-p140) (18.4%, 9/49) and anti-155/140-kDa polypeptide (anti-p155/140) (16.3%, 8/49) antibodies were the most common, followed by anti-Mi2 (14.3%, 7/49), anti-ARS (12.2%, 6/49) and anti-SRP (2.0%, 1/49) antibodies. All MSAs and anti-p140 and anti-p155/140 antibodies were mutually exclusive. Anti-p140 (23.7%, 9/38), anti-p155/140 (21.1%, 8/38), and anti-Mi2 (18.4%, 3/38) antibodies were found exclusively in DM patients. Anti-p140 antibody was associated with rapidly progressive interstitial lung disease (ILD) (p = 0.001), with a sensitivity of 100.0% (4/4) and a specificity of 85.3% (29/34) in DM patients. Anti-p155/140 antibody was associated with cancer-associated DM (p = 0.009), with a sensitivity of 55.6% (5/9) and a specificity of 89.7% (26/29). Cancer-associated survival was significantly worse when anti-p155/140 antibody was present (19.2 ± 7.6 vs. 65.0 ± 3.5 months, p = 0.032). Finally, anti-ARS antibodies were associated with stable or slowly progressive ILD in PM and DM patients (p = 0.005).</p> <p>Conclusions</p> <p>Anti-p140 and anti-p155/140 antibodies were commonly found autoantibodies in Korean patients with inflammatory myositis. Despite the lack of clinically amyopathic DM patients in the study subjects, a strong association was observed between anti-p140 antibody and rapidly progressive ILD. Anti-p155/140 antibody was associated with cancer-associated myositis and poor survival.</p> |
url |
http://www.biomedcentral.com/1471-2474/11/223 |
work_keys_str_mv |
AT leeyun myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis AT kimjinhyun myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis AT mimoritsuneyo myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis AT nakashimaran myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis AT kangeun myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis AT leeeun myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis AT songyeong myositisautoantibodiesinkoreanpatientswithinflammatorymyositisanti140kdapolypeptideantibodyisprimarilyassociatedwithrapidlyprogressiveinterstitiallungdiseaseindependentofclinicallyamyopathicdermatomyositis |
_version_ |
1716797283088990208 |